Digitised Home Based Care for Parkinson's Disease

Parkinson's disease is the world's fastest-growing neurological condition. It is a progressive neurodegenerative disorder that causes a wide range of movement-related (motor) problems (slowness, stiffness, tremor, balance difficulties) and non-motor problems (disturbances of thinking, memory, perception, mood, bladder, bowels, blood pressure). Even before the pandemic, NHS services were struggling to meet the demand for care.

To address this need for support, the investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), with people with Parkinson's (PwP) and care partners (CP) to deliver self-management support and clinical expertise to the patient's home. This pathway is supported by remote monitoring with a wrist-worn sensor and questionnaires.

In this study, the investigators will be digitising this pathway so that data from a variety of sources (including the sensor, questionnaires, and patients' health records) can be combined in one place to enable more personalised care and to provide advice to support self-management of symptoms by patients.

After the investigators have set up the digitised pathway, its implementation will be evaluated with a group of 120 people with Parkinson's and their care partners and associated healthcare providers through the Plymouth Parkinson's Service. The investigators will examine participants' adoption of and engagement with the patient-facing digital platform over the course of 3 months and gather their feedback about its usability and acceptability. A smaller group of the participants will discuss their experiences in more detail to help pinpoint aspects that work well and those needing adjustment and development.

The investigators anticipate that this system will result in improved quality of life and care and increased knowledge and confidence for self-managing symptoms. The results of the study will be used to improve the digitised Home Based Care pathway. People with Parkinson's and care partners involved in the project will help guide the sharing of these results with healthcare providers and the general public.

Study Overview

• Status: Not yet recruiting
• Conditions: Parkinson Disease; Parkinson
• Intervention / Treatment: Other: Digital Home Based Care pathway

• Study Type: Interventional
• Enrollment (Anticipated): 120
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Edward Meinert, PhD; Phone Number: 01752600600; Email: edward.meinert@plymouth.ac.uk
• Study Contact Backup: Name: Madison Milne-Ives, MSc; Phone Number: 01752600600; Email: madison.milne-ives@plymouth.ac.uk

Study Locations

• United Kingdom
  • Devon
    • Plymouth, Devon, United Kingdom, PL4 6DN
      • University of Plymouth

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Age 18 years or over
• Not resident in care home or nursing home
• Ambulant
• Have compatible smartphone/data access (access to a digital device is a necessary prerequisite of system use, and the formative usability study had success in recruiting participants with varying levels of experience with smartphones [18])
• Be fluent in English
• Normally under the care of the Parkinson's service in the participating organisation
• Participant's healthcare provider in the participating organisation consented to participate in the study
• Able and willing to provide informed consent
• Able and willing to comply with intervention requirements

Exclusion Criteria:

• Secondary cause of parkinsonism
• Significant cognitive impairment or a diagnosis of Parkinson's disease dementia
• Significant comorbidity, which in the opinion of the chief investigator would preclude safe participation in the study or protocol compliance
• Previous involvement in development or testing of the NMS Assist system
• A life expectancy of <6 months
• Living in residential care facilities
• Incapable of self-consent
• In a dependent/unequal relationship with the research or care teams or any PPI representatives

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Supportive Care
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Digitised Home Based Care pathway; The investigators have co-designed an innovative digital care pathway, Home Based Care (HBC), that delivers self-management support and clinical expertise to the patient's home, supported by digitally-enabled remote monitoring with a wrist-worn sensor, the Parkinson's Kinetograph, and digitally-delivered questionnaires, to replace the current pen-and-paper processes.

Other: Digital Home Based Care pathway; The digital version of the pathway includes an integrated data platform with an automated patient flow management system, digitised patient-reported outcome on web-based patient portal, and AI-based automated reporting for clinical decision support.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Uptake	Rates of conversion to the digital platform	3 months
Degree of compliance with wearable sensor	The wearable sensors are worn on the wrist and are known as the Parkinson's Kinetograph (PKG). The PKG assess objective motor measures including bradykinesia, dyskinesia and tremor. In accordance with the HBC pathway, patients are required to wear the PKG for 6 days and nights, after which the results are analyzed by their care team. From these results, therefore, it is clear to see where the patient has complied with wearing the PKG for the allotted time frame.	3 months
Proportion of digital questionnaires completed	In accordance with HBC pathway, patients are required to complete a set of questionnaires covering the same time period in which they are wearing the PKG, and are responsible for assessing subjective measures. This outcome will assess compliance by examining the patients' overall compliance with the digital monitoring questionnaires by calculating how many of the questionnaires they successfully complete over the study period.	3 months
Engagement	Qualitative feedback about engagement from semi-structured interviews	3 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Usability scores	System Usability Scale, 5-point Likert scale with total scores ranging from 0-100	3 months
Patient perceptions of usability	Qualitative feedback about usability from semi-structured interviews	3 months
Patient perceptions of acceptability	Qualitative feedback about acceptability from semi-structured interviews	3 months
Cost impact	Preliminary evaluation of implementation costs; costs required to implement the digital HBC pathway will be compared to the costs of delivering the standard care pathway	3 months

Collaborators and Investigators

• Sponsor: University of Plymouth
• Investigators: Principal Investigator: Camille Carroll, PhD, University of Plymouth

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2024
• Primary Completion (Anticipated): June 1, 2025
• Study Completion (Anticipated): June 1, 2025

Study Registration Dates

• First Submitted: September 1, 2022
• First Submitted That Met QC Criteria: September 14, 2022
• First Posted (Actual): September 16, 2022

Study Record Updates

• Last Update Posted (Estimate): May 11, 2023
• Last Update Submitted That Met QC Criteria: May 10, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: Telemedicine; Parkinson Disease; Self-Management; Artificial Intelligence
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Parkinsonian Disorders; Basal Ganglia Diseases; Movement Disorders; Synucleinopathies; Neurodegenerative Diseases; Parkinson Disease
• Other Study ID Numbers: PEOS-3289

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: Only the project leads and associated staff will have access to the research data and healthcare professionals participating in the study will have access only to the data from the PwP and care partners whom they are treating.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No